According to Fortune Business Insights, the global Gallbladder Cancer Treatment Market size was valued at USD 908.0 million in 2025. The market is projected to grow from USD 1,028.0 million in 2026 to USD 2,287.0 million by 2034, exhibiting a CAGR of 10.51% during the forecast period 2026–2034. Asia Pacific dominated the market in 2025, accounting for a 36.08% market share. The market is expanding as gallbladder cancer is frequently diagnosed at an advanced stage, increasing the need for systemic treatment options such as chemotherapy, immunotherapy, targeted therapy, and combination regimens.
The Gallbladder Cancer Treatment Market includes therapies administered across different stages and treatment settings. Key drugs covered by the market include gemcitabine, cisplatin, durvalumab, pembrolizumab, capecitabine, oxaliplatin, fluorouracil, zanidatamab, and trastuzumab deruxtecan.
The market is characterized by continued reliance on conventional chemotherapy alongside the growing adoption of immunotherapy and targeted therapy. Gemcitabine and cisplatin remain important components of treatment for unresectable and metastatic disease, while the addition of immune checkpoint inhibitors is expanding first-line treatment options.
The market is segmented by drug, drug class, therapy, route of administration, age group, distribution channel, and region.
For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/gallbladder-cancer-treatment-market-101001
Increasing pharmaceutical investment in rare and advanced cancers is a prominent trend in the market. The relatively small patient population, aggressive disease progression, late diagnosis, and limited treatment alternatives are encouraging pharmaceutical companies to develop therapies applicable to broader biliary tract cancer populations.
Companies are evaluating targeted antibodies, immunotherapy combinations, novel drug-delivery systems, and biomarker-based treatments. Regulatory support for therapies addressing serious and rare diseases is also encouraging continued clinical development.
For example, in July 2025, FUJIFILM Pharmaceuticals U.S.A. received orphan drug designation from the U.S. FDA for FF-10832, an investigational liposomal formulation of gemcitabine for biliary tract cancer.
The increasing use of chemo-immunotherapy as a first-line treatment is a major factor driving market growth. Patients with unresectable, locally advanced, or metastatic gallbladder cancer have traditionally relied on gemcitabine- and cisplatin-based chemotherapy.
The addition of immune checkpoint inhibitors to chemotherapy can strengthen the antitumor immune response and improve survival compared with chemotherapy alone. As these combination regimens become integrated into treatment guidelines and adopted across more countries, immunotherapy utilization is expected to increase.
The rising global cancer burden, expansion of approved biosimilar portfolios, price discounts, institutional reimbursement frameworks, and future loss of exclusivity for checkpoint inhibitors are also identified as factors influencing market growth.
However, low disease incidence and frequent late-stage diagnosis restrict the commercially addressable patient population. The source notes that only around 10%–20% of patients may be eligible for curative surgical resection at diagnosis, further limiting the treatment pool.
Based on drug, the market is segmented into gemcitabine, cisplatin, durvalumab, pembrolizumab, capecitabine, oxaliplatin, fluorouracil, zanidatamab, trastuzumab deruxtecan, and others.